<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05038371</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00255963</org_study_id>
    <nct_id>NCT05038371</nct_id>
  </id_info>
  <brief_title>Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration</brief_title>
  <official_title>Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Olix Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Age-related macular degeneration (AMD) remains a leading cause of blindness in United States&#xD;
      and can be broadly divided into two forms: non-neovascular AMD (NNVAMD) and neovascular AMD&#xD;
      (NVAMD) AMD. Among the several mechanisms underlying AMD, hypoxia and oxidative stress have&#xD;
      been implicated and cause upregulation of several signaling proteins. About 20% of patients&#xD;
      with NNVAMD develop choroidal neovascularization and hence convert to NVAMD. Upregulation of&#xD;
      vascular endothelial growth factor (VEGF) plays a critical role in conversion from NNVAMD to&#xD;
      NVAMD.&#xD;
&#xD;
      Connective tissue growth factor (CTGF) is a polypeptide that has been shown to be&#xD;
      overexpressed in various fibrotic disorders, suggesting its involvement in scarring. After&#xD;
      the development of choroidal neovascularization, subretinal fibrosis may occur and result in&#xD;
      permanent reduction of vision. An important question is, does CTGF contribute to subretinal&#xD;
      fibrosis. An important first step in addressing this question is to determine if CTGF levels&#xD;
      are increased in the eyes of patients with NVAMD and this is the objective of this study.&#xD;
&#xD;
      The investigators plan to measure levels of connective tissue growth factor (CTGF) in the&#xD;
      aqueous humor of patients with neovascular age-related macular degeneration and compare to&#xD;
      controls. Levels of VEGF will be measured as a positive control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of aqueous humor levels of CTGF by ELISA</measure>
    <time_frame>Baseline visit</time_frame>
    <description>Connective tissue growth factor (CTGF) levels will be measured, using ELISA, in aqueous samples of both patients and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of aqueous humor levels of VEGF by ELISA</measure>
    <time_frame>Baseline visit</time_frame>
    <description>Vascular endothelial growth factor (VEGF) levels will be measured, using ELISA, in aqueous samples of both patients and controls. Levels of VEGF will serve as a positive control.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Wet Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Patients with neovascular age-related macular degeneration</arm_group_label>
    <description>This will include 10 subjects with a diagnosis of age-related macular degeneration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>This group will comprise 10 participants who plan to undergo vitrectomy for macular hole, macular pucker, or vitreomacular traction, vitreous floaters or another condition unrelated to scarring.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples will only be used for measurement of biomarkers mentioned.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A total of twenty eligible patients, 10 with NVAMD and 10 controls will be enrolled.&#xD;
&#xD;
        Patients and controls will be identified and recruited through the clinic population of&#xD;
        co-investigators at the Wilmer Eye Institute.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;/= 18 years&#xD;
&#xD;
          -  Willing to sign informed consent and authorization of use and disclosure of protected&#xD;
             health information&#xD;
&#xD;
          -  For study group: patients must have a clinical diagnosis of NVAMD&#xD;
&#xD;
          -  For control group: patients undergoing vitrectomy for macular hole, macular pucker, or&#xD;
             vitreomacular traction, vitreous floaters or another condition unrelated to scarring.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a retinal condition other than NVAMD in which scarring may occur such as&#xD;
             proliferative vitreoretinopathy or retinal detachment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter A Campochiaro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gulnar Hafiz, M.D., M.P.H.</last_name>
    <phone>4105020768</phone>
    <email>ghafiz@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wilmer Eye Institute at Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gulnar Hafiz, M.D., M.P.H.</last_name>
      <phone>410-502-0768</phone>
      <email>ghafiz@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Peter A Campochiaro, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

